Alkermes PLC

NAS: ALKS

GO
/marketstate/country/us

After Hours

/zigman2/quotes/205084517/composite

$

16.63

Change

0.00 0.00%

Volume

Volume 38,084

Jun 1, 2020, 4:33 p.m.

Real time quotes

/zigman2/quotes/205084517/composite

Today's close

$ 16.36

$ 16.63

Change

+0.27 +1.65%

Day low

Day high

$16.15

$16.80

Open
Open: 16.34

52 week low

52 week high

$11.98

$25.35

Open

Market cap

$2.60B

Average volume

1.69M

P/E ratio

N/A

Rev. per Employee

$475,771

EPS

-0.88

Dividend

N/A

Div yield

N/A

Ex dividend date

N/A

Compare:
Indexes
  • Dow(INDU) INDU
  • Nasdaq (COMP) COMP
  • S&P 500 (SPX) SPX
  • Global Dow (GDOW) GDOW
1d
5d
3m
6m
1y
3y
5y
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. Alkermes downgraded to neutral from buy at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  2. Alkermes stock price target cut to $20 from $31 at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  3. Alkermes downgraded to neutral from overweight at J.P. Morgan

    8:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  4. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    8:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  5. FDA told Alkermes to stop publishing Vivitrol ad

    1:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  6. Alkermes to acquire Rodin Therapeutics for up to $950 million

    8:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  7. Biogen shares fall 3%

    4:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  8. Biogen, Alkermes MS treatment Vumerity gets FDA approval

    7:33 a.m. Oct. 30, 2019

    - Tomi Kilgore

  9. Alkermes upgraded to equal weight at Morgan Stanley

    10:09 a.m. Sept. 5, 2019

    - Tomi Kilgore

  10. Alkermes stock price target cut to $34 from $40 at Stifel Nicolaus

    8:55 a.m. Feb. 15, 2019

    - Tomi Kilgore

  11. Alkermes shares fall after FDA blocks antidepressant approval

    5:56 p.m. Feb. 1, 2019

    - Wallace Witkowski

  12. Alkermes reports positive results in late-stage trial of schizophrenia treatment

    8:01 a.m. Nov. 29, 2018

    - Ciara Linnane

  13. Alkermes halted premarket for news pending

    7:57 a.m. Nov. 29, 2018

    - Ciara Linnane

  14. Loading more headlines...

Analyst Ratings

/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat

    11:12 a.m. April 30, 2020

    - Zacks.com

  2. Alkermes plc 2020 Q1 - Results - Earnings Call Presentation

    9:55 a.m. April 29, 2020

    - Seeking Alpha

  3. 10-Q: ALKERMES PLC.

    9:27 a.m. April 29, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  4. Notable earnings before Wednesday's open

    5:30 p.m. April 28, 2020

    - Seeking Alpha

  5. Alkermes Q1 2020 Earnings Preview

    5:30 p.m. April 28, 2020

    - Seeking Alpha

  6. What's in Store for Innoviva (INVA) This Earnings Season?

    11:58 a.m. April 28, 2020

    - Zacks.com

  7. ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

    11:40 a.m. April 28, 2020

    - Zacks.com

  8. Why Alkermes (ALKS) Might Surprise This Earnings Season

    8:49 a.m. April 22, 2020

    - Zacks.com

  9. Alkermes: Lack Of Near-Term Catalysts

    2:54 p.m. March 13, 2020

    - Seeking Alpha

  10. U.S. credit markets endure worst decade in 10 years

    3:12 p.m. March 6, 2020

    - Seeking Alpha

  11. U.S. credit markets endure worst day in 10 years

    3:12 p.m. March 6, 2020

    - Seeking Alpha

  12. Stocks To Watch: Time For Coronavirus Offense Or Defense?

    9:26 a.m. Feb. 29, 2020

    - Seeking Alpha

  13. IPO Update: Passage Bio Finalizes $126 Million IPO Plan

    4:57 p.m. Feb. 18, 2020

    - Seeking Alpha

  14. BofA and JPM cut views on Alkermes in premarket analyst action

    8:53 a.m. Feb. 14, 2020

    - Seeking Alpha

  15. Loading more headlines...
/news/pressrelease/company/us/alks

Press Releases on ALKS

  1. Europe Drug Delivery Market Analysis as per the Latest COVID-19 Impact

    10:50 a.m. Today

    - Heraldkeepers

  2. Baudax Bio Secures $50 Million Credit Facility

    7:01 a.m. Today

    - GlobeNewswire

  3. Loading more headlines...

Rates »

Link to MarketWatch's Slice.